Participants
| Role | Name | HCID | Charge |
|---|
| Reactant | Sodium Carbonate | HCID 10340 | — |
| Reactant | HCID 20516774 | HCID 20516774 | — |
| Reactant | HCID 20516775 | HCID 20516775 | — |
| Reactant | HCID 20516784 | HCID 20516784 | — |
| Solvent | 1,2-Dichloroethane | HCID 11 | — |
| Solvent | 1,1-Dichloroethane | HCID 6365 | — |
| Solvent | 2-Morpholinoethylamine | HCID 408285 | — |
| Product | HCID 20516777 | HCID 20516777 | — |
Reaction Steps
A 1,2-dichloroethane solution of [6,8-dichloro-5-(o-fluorophenyl)-2,3-dihydro-1-methyl-2-oxo-1H-1,4-benzodiazepin-7-yl]isocyanate, prepared in analogy to the procedure described in paragraph (a) of Example 4 from 5.5 g (15.62 mmol) of 7-amino-6,8-dichloro-5-(o-fluorophenyl)-1,3-dihydro-1-methyl-2H-1,4-benzodiazepin-2-one, is treated at room temperature all at once with a suspension of 6.11 g of sodium carbonate in 6.1 ml of N-(2-aminoethyl)morpholine and 40 ml of dichloroethane and the mixture is stirred for 114 hours. The mixture is extracted with methylene chloride/ethanol (4:1), the organic phase is washed with water, dried and evaporated. The residue is chromatographed on 250 g of silica gel using chloroform for the elution, there being obtained 1-[6,8-dichloro-5-(o-fluorophenyl)-2,3-dihydro-1-methyl-2-oxo-1H-1,4-benzodiazepin-7-yl]-3-(2-morpholinoethyl)urea. After recrystallisation from ether, the product melts at 174°-176° C.
Provenance & Evidence
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| Patent number | US04361511 |
|---|
| Source dataset | uspto-grants-1982_11 |
|---|
| ORD ID | ord-cad937b0f1da4dc4832ae8df1e09eae3 |
|---|
| Source note | uspto-grants-1982_11 |
|---|